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An earlier report identiﬁed higher risks of acute and chronic graft-versus-host disease (GVHD) in White
children compared with the Japanese after HLA-matched sibling transplantations. The current analysis
explored whether racial differences are associated with GVHD risks after unrelated umbilical cord blood
transplantation. Included are patients of Japanese descent (n ¼ 257) and Whites (n ¼ 260; 168 of 260 received
antithymocyte globulin [ATG]). Transplants were performed in the United States or Japan between 2000 and
2009; patients were aged 16 years or younger, had acute leukemia, were in complete remission, and received
a myeloablative conditioning regimen. The median ages of the Japanese and Whites who received ATG were
younger at 5 years compared with 8 years for Whites who did not receive ATG. In all groups most transplants
were mismatched at 1 or 2 HLA loci. Multivariate analysis found no differences in risks of acute GVHD
between the Japanese and Whites. However, chronic GVHD was higher in Whites who did not receive ATG
compared with the Japanese (hazard ratio, 2.16; P < .001), and treatment-related mortality was higher in
Whites who received ATG compared with the Japanese (relative risk, 1.81; P ¼ .01). Nevertheless, there were
no signiﬁcant differences in overall survival between the 3 groups.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Graft-versus-host disease (GVHD) after allogeneic he-
matopoietic stem cell transplantation is associated with
signiﬁcant morbidity andmortality [1]. Acute GVHD risks are
higher after HLA-mismatched compared with HLA-matched
transplantations and primarily attributed to mismatching at
major histocompatibility antigens. On the other hand,
donorerecipient mismatching for minor histocompatibility
antigens may explain GVHD after HLA-matched trans-
plantations. In an earlier report, Oh et al. [2] compared GVHD
and overall survival between different ethnic populations
after HLA-matched related bone marrow transplantation foredgments on page 666.
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14.01.020hematologic malignancies. That report, which included
children and adults, showed higher acute but not chronic
GVHD risks for adult U.S. Whites compared with adults of
Japanese descent. However, among children, both acute and
chronic GVHD risks were higher in U.S. Whites compared
with the Japanese. In that report, the observed differences
between the Japanese and Whites were attributed to the
relative homogeneity of minor histocompatibility antigens in
persons of Japanese descent [3].
Umbilical cord blood (UCB) is less immunogenic, and
consequently HLA mismatches that are prohibitive between
unrelated adult donors and recipients are considered
acceptable up to 2 mismatches when selecting UCB units.
The practice of transplanting UCB units (UCBT) that are HLA
mismatched to recipients is common in both children and
adults worldwide [4-8]. To our knowledge, no published
reports explore whether racial differences exist in acute andTransplantation.
Table 1
Characteristics of Study Patients
Japanese
(n ¼ 257)
White,
with ATG
(n ¼ 168)
White,
no ATG
(n ¼ 92)
P
Age at transplant, yr <.0001
5 135 (53%) 85 (51%) 25 (27%)
6-16 122 (47%) 83 (49%) 67 (73%)
Gender .73
Female 116 (45%) 81 (48%) 40 (43%)
Male 141 (55%) 87 (52%) 52 (57%)
Recipient CMV status <.0001
Negative 78 (30%) 88 (52%) 43 (47%)
Positive 115 (45%) 80 (48%) 48 (52%)
Unknown 64 (25%) d 1 (1%)
Disease <.0001
AML 70 (27%) 88 (52%) 23 (25%)
ALL 187 (73%) 80 (48%) 69 (75%)
Disease risk <.0001
CR1 156 (61%) 61 (36%) 32 (35%)
CR2/CR3 101 (39%) 107 (64%) 60 (65%)
Year of transplant <.0001
2000-2006 174 (68%) 105 (63%) 27 (29%)
2007-2009 83 (32%) 63 (38%) 65 (71%)
No. of cryopreserved
TNCs 107/kg
<.0001
<3 48 (19%) 4 (2%) 9 (10%)
3 201 (78%) 164 (98%) 83 (90%)
Unknown 8 (3%) d d
HLA match status (A B;
intermediate
resolution, DRB1;
allele level)
.51
6/6 47 (18%) 42 (25%) 17 (18%)
5/6 127 (49%) 75 (45%) 47 (51%)
4/6 83 (32%) 51 (30%) 28 (30%)
Conditioning regimen <.0001
Non-TBI 75 (29%) 74 (44%) 8 (9%)
TBI 182 (71%) 94 (56%) 84 (91%)
GVHD prophylaxis <.0001
Cyclosporine
containing
122 (47%) 138 (82%) 54 (59%)
Tacrolimus
containing
135 (53%) 30 (18%) 38 (41%)
Median follow-up of
survivors, mo
(range)
<.0001
61 (10-138) 52 (12-123) 36 (13-85)
CMV indicates cytomegalovirus; AML, acute myeloid leukemia; ALL, acute
lymphoblastic leukemia.
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Japan are from cord blood banks in Japan, allowing for a
homogeneous cohort of donors. On the other hand, the U.S.
population is genetically diverse, and UCB units may have
been obtained through either a U.S. or international cord
blood bank. Additionally, differences in transplantation
strategies exist. In Japan, UCB units generally contain fewer
total nucleated cells (TNCs) than in the United States and
consider lower resolution HLA match (antigen level) at HLA-
A, -B, and -DR. In the United States, HLA matching at the DR
locus considers allele-level match. Additionally, antithymo-
cyte globulin (ATG) was routinely included in the transplant
preparatory regimen before 2007 in the United States [8,9].
Another key difference between the 2 countries is the co-
infusion of 2 UCB units, routine in the United States, for
adults. Consequently, the current analysis is limited to
younger patients such that the comparison is between
appropriately aged patients who were transplanted with a
single UCB unit. In this report we compare acute and chronic
GVHD and mortality risks after UCBT between Japanese and
White children with acute leukemia to test whether the ge-
netic diversity of donors and recipients inﬂuenced the like-
lihood of GVHD.
METHODS
Data Source
Data were obtained from the Center for International Blood andMarrow
Transplant Research [10] for U.S. transplants and from the Japan Society for
Hematopoietic Cell Transplantation (JSHCT) and the Japan Cord Blood Bank
Network [11] for Japanese transplants. All U.S. patients provided consent for
research participation. Patient consent is not required for registration of the
JSHCT because registry data consist of anonymized clinical information. The
institutional review board of the National Marrow Donor Program, Medical
College of Wisconsin, Nagoya University Graduate School of Medicine, and
the Data Management Committees of the JSHCT and the Japan Cord Blood
Bank Network approved this study.
Inclusion Criteria
Patients were 16 years old and younger with acute myeloid leukemia or
acute lymphoblastic leukemia and in ﬁrst, second, or third complete
remission (CR). All patients received a myeloablative transplant condition-
ing regimen and were transplanted in Japan or the United States between
2000 and 2009. Excluded were non-Whites transplanted in the United
States, transplantations in relapse, prior allogeneic transplantation, infusion
of 2 UCB units, or reduced-intensity transplant conditioning regimens. Five
hundred seventeen patients were eligible: 257 transplants from Japan, 168
transplants forWhites that included ATG in their transplant regimen, and 92
transplants for Whites without ATG. Units were matched to patients at the
antigen level at HLA-A and -B and at the allele level at HLA-DRB1; for the
Japanese cohort, this occurred retrospectively.
Outcomes
Acute and chronic GVHD were deﬁned as time to occurrence of GVHD,
using standard criteria [12,13]. Treatment-related mortality (TRM) was
deﬁned as death without leukemia relapse. Relapse was deﬁned as hema-
tological/morphological recurrence of leukemia. Overall mortality was
deﬁned as death from any cause.
Statistical Analysis
To compare the outcomes of interest, Cox proportional hazards models
were used to adjust for potential imbalance in baseline characteristics be-
tween the 3 treatment groups [14,15]. The main effect term, Japanese versus
Whites who received ATG versus Whites who did not receive ATG, was held
in all steps of model building regardless of level of signiﬁcance. Other var-
iables considered were age at transplantation (5 versus 6 to 16 years),
gender, recipient cytomegalovirus (CMV) serostatus, disease, disease status,
TNCs (3 versus >3  107/kg), HLA match (6/6 versus 5/6 versus 4/6),
transplant preparative regimen (containing total body irradiation [TBI]
versus not), GVHD prophylaxis (containing cyclosporine versus tacrolimus),
and period (2000 to 2006 versus 2007 to 2009). All variables met the pro-
portionality assumption, and there were no ﬁrst-order interactions between
variables in the ﬁnal model and the main effect term. The effects of acute
and chronic GVHD were also tested for their effect on overall mortality astime-dependent covariates. Results are expressed as hazard ratios (HRs)
together with 95% conﬁdence intervals (CIs).
Adjusted cumulative incidences of acute GVHD, chronic GVHD, relapse,
and TRM [16] and adjusted probabilities of survival [17] were calculated
using the multivariate models, stratiﬁed on the 3 treatment groups, and
weighted by the pooled sample proportion value for each prognostic factor.
SAS version 9.3 (Cary, NC) was used in the analyses.
RESULTS
Table 1 shows characteristics of patients, their diseases,
and transplant regimens by the 3 treatment groups: Japa-
nese, Whites who received ATG, and Whites who did not
receive ATG. None of the Japanese patients received ATG. The
median ages of the Japanese and Whites who received ATG
was 5 years, whereas Whites who did not receive ATG were
slightly older at 8 years.
There were other differences: Japanese patients were
more likely to be CMV seropositive, to be transplanted in ﬁrst
CR, and more likely to receive a UCB unit with TNCs <
3  107/kg compared with Whites. Median TNC doses were
5.1 107/kg (range, 1.3 to 48), 7.4  107/kg (range, 1.6 to 50),
and 5.7  107/kg (range, 1.6 to 21) for Japanese, Whites who
received ATG, and Whites who did not receive ATG,
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dominant indication for the Japanese and Whites after 2006.
Differences were found in GVHD prophylaxis. About half of
the Japanese patients received tacrolimus-containing GVHD
prophylaxis, whereas most Whites used cyclosporine-
containing GVHD prophylaxis. There were no signiﬁcant dif-
ferences in degree of donorerecipient HLA match by race;
about half of all transplants were mismatched at a single HLA
locus and about a third were mismatched at 2 HLA loci. The
median follow-up for Whites who did not receive ATG was
3 years compared with 4 years Whites who received ATG and
5 years for the Japanese.Acute and Chronic GVHD
Therewere no signiﬁcant differences in the risks of grades
II to IV and grades III to IV acute GVHD among the 3 groups
(Table 2). No other factors were associated with grades II to
IV acute GVHD, but grades III to IV acute GVHD risks were
higher for patients aged 6 to 16 years compared with
younger patients (HR, 1.93; 95% CI, 1.19 to 3.14; P ¼ .008) and
boys (HR, 1.71; 95% CI, 1.07 to 2.75; P ¼ .03). The 100-day
adjusted cumulative incidences of grades II to IV acute
GVHD were 38% (95% CI, 32% to 43%), 37% (95% CI, 30% to
44%), and 45% (95% CI, 35% to 55%) for the Japanese, Whites
who received ATG, and Whites who did not receive ATG,
respectively (Figure 1A). The corresponding probabilities for
grades III to IV acute GVHDwere 14% (95% CI, 10% to 19%), 18%
(95% CI, 13% to 24%), and 12% (95% CI, 7% to 19%, Figure 1B).
Chronic GVHD risks differed by transplant strategy.
Compared with the Japanese, risks were signiﬁcantly higher
in Whites who did not receive ATG (HR, 2.16; 95% CI, 1.40 to
3.32; P < .001) than for Whites who received ATG (Table 2).
There were no differences in the severity of chronic GVHD;
among those with chronic GVHD, the proportion of patients
with extensive chronic GVHD was 33% for the Japanese, 48%
for Whites receiving ATG, and 44% for Whites who did not
receive ATG (P ¼ .28). The 3-year cumulative incidences ofTable 2
Multivariate Analysis of Acute and Chronic GVHD, TRM, Relapse, and Overall
Mortality
Number HR (95% CI) P
Grades II-IV acute GVHD
Japanese 249 1.00 Reference
Whites, received ATG 167 .93 (.68-1.28) .64
Whites, did not receive ATG 91 1.27 (.88-1.82) .20
Grades III-IV acute GVHD
Japanese 251 1.00 Reference
White, with ATG 167 1.34 (.82-2.18) .25
White, no ATG 91 .93 (.50-1.75) .83
Chronic GVHD
Japanese 245 1.00 Reference
White, with ATG 163 1.43 (.96-2.14) .08
White, no ATG 88 2.16 (1.40-3.32) <.001
TRM
Japanese 242 1.00 Reference
White, with ATG 167 1.81 (1.16-2.83) .01
White, no ATG 91 1.28 (.74-2.22) .39
Relapse
Japanese 242 1.00 Reference
White, with ATG 167 .92 (.62-1.35) .66
White, no ATG 91 .77 (.47-1.28) .32
Overall mortality*
Japanese 253 1.00 Reference
White, with ATG 167 1.40 (1.00-1.94) .05
White, no ATG 91 1.17 (.78-1.76) .45
* Two degrees of freedom overall test for overall mortality showed no
statistical signiﬁcance (P ¼ .14).
Figure 1. Cumulative incidence of GVHD after single-unit UCBT. (A) Cumula-
tive incidences of grades II to IV acute GVHD. (B) Cumulative incidences of
grades III to IV acute GVHD. (C) Cumulative incidences of chronic GVHD.chronic GVHDwere 21% (95% CI, 16% to 26%) for the Japanese,
27% (95% CI, 20% to 34%) for Whites who received ATG, and
40% (95% CI, 30% to 50%) for Whites who did not receive ATG
(Figure 1C).
TRM and Relapse
Compared with the Japanese, risks of TRM were signiﬁ-
cantly higher for Whites who received ATG but not for
Whites who did not receive ATG (Table 2). Independent of
geographical region and use of ATG, transplantations mis-
matched at 2 HLA loci (HR, 2.17; 95% CI, 1.14 to 4.12; P ¼ .02)
were associated with higher TRM compared with HLA-
matched transplantations. TBI-containing regimens were
also associated with higher TRM compared with non-TBI
regimens (HR, 2.26; 95% CI, 1.32 to 3.89; P ¼ .003). The 3-
year cumulative incidence of TRM was 15% (95% CI, 11% to
20%) for the Japanese, 26% (95% CI, 19% to 33%) for Whites
who received ATG, and 19% (95% CI, 12% to 28%) for Whites
who did not receive ATG (Figure 2A). Relapse risks were not
different among the 3 groups (Table 2). Relapse was associ-
ated with disease status at transplantation; transplants in
second or third CR were associated with higher risks
compared with ﬁrst CR (HR,1.61; 95% CI, 1.12 to 2.30; P¼ .01).
Figure 2. Cumulative incidence of TRM and overall survival curves. (A) Cu-
mulative incidences of TRM. (B) Probability of overall survival after single-unit
UCBT adjusted for CMV-seropositive status and disease risk at transplantation.
Table 3
Causes of Death
Japanese
(n ¼ 257)
White, with
ATG (n ¼ 168)
White, no
ATG (n ¼ 92)
Total death 93 82 37
Relapse 54 (58%) 41 (50%) 18 (49%)
Graft failure 3 (3%) 1 (1%) 5 (14%)
GVHD 9 (10%) 14 (17%) 2 (5%)
Infection 10 (11%) 11 (13%) 9 (24%)
Ipn/ARDS 8 (9%) 2 (2%) 2 (5%)
Organ failure 6 (6%) 9 (11%) 1 (3%)
Others* 2 (2%) 3 (3%) d
Unknown 1 (1%) 1 (1%) d
Ipn indicates interstitial pneumonitis; ARDS, acute respiratory distress
syndrome.
* Other causes in Japanese include hemorrhage, n ¼ 1, and thrombocytic
microangiopathy, n ¼ 1; in Whites with ATG include intracranial hemor-
rhage, n ¼ 1; Epstein-Barr viruseassociated lymphoproliferative disorder,
n ¼ 1; and anaplastic astrocytoma, n ¼ 1.
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23% to 34%) for the Japanese, 26% (95% CI, 20% to 33%) for
Whites who received ATG, and 22% (95% CI, 14% to 31%) for
Whites who did not receive ATG.Overall Mortality
After adjusting for CMV serostatus and disease status at
transplantation, factors associated with overall mortality,
there were no differences in mortality risks between the
Japanese and Whites who did not receive ATG (Table 2).
However, the observedmarginal increase in overall mortality
risk for Whites who received ATG compared with the Japa-
nese must be interpreted with caution. The level of signiﬁ-
cance for the overall mortality model did not reach the level
of signiﬁcance set for this analysis (P ¼ .14; 2 degrees of
freedom test). Consequently, any observed differences be-
tween exposure categories within the model are suspect and
call for conﬁrmation in an independent data set. Indepen-
dent of region, mortality risks were higher for patients who
were CMV seropositive (HR, 1.57; 95% CI, 1.16 to 2.11;
P ¼ .003) and for transplantations in second or third CR (HR,
1.54; 95% CI, 1.15 to 2.06; P ¼ .003).
We also tested for the effect of acute (grades II to IV: HR,
1.19; 95% CI, .90 to 1.57; P ¼ .23, grades III to IV: HR, 1.38; 95%
CI, .96 to 1.98; P ¼ .08) and chronic GVHD (HR, 1.14; 95% CI,
.78 to 1.65; P ¼ .5) on overall mortality and found none. The
3-year probabilities of overall survival adjusted for CMV
serostatus and disease status at transplantation were 63%
(95% CI, 57% to 69%) for the Japanese, 54% (95% CI, 46% to
62%) for Whites who received ATG, and 60% (95% CI, 49% to
70%) for Whites who did not receive ATG (Figure 2B). Table 3
shows the causes of death. Relapse was the most frequent
cause of death in all groups and accounted for about half ofall deaths in all groups. The most frequent causes of non-
relapse death for Japanese and Whites who received ATG
were infection, GVHD, interstitial pneumonitis, and organ
failure. On the other hand, for Whites who did not receive
ATG, graft failure and infection were the most frequent
causes of nonrelapse deaths.
The day-28 cumulative incidences of neutrophil recovery
were higher for the Japanese (76%; 95% CI, 71% to 81%)
comparedwithWhiteswho receivedATG (66%; 95%CI, 59% to
73%;P¼ .02) andWhiteswhodidnot receiveATG (53%;95%CI,
43% to 63%; P < .001). However, by day 42 cumulative in-
cidences of neutrophil recovery were not different between
the Japanese (88%; 95% CI, 84% to 92%) and Whites who
received ATG (84%; 95% CI, 79% to 90%; P¼ .31) and thosewho
did not receive ATG (82%; 95% CI, 74% to 90%; P ¼ .22).
DISCUSSION
The current analyses, in children with acute leukemia,
sought to identify differences in acute and chronic GVHD
risks after UCBT in a relatively homogenous population, the
Japanese, to a more genetically diverse population, Whites.
Three major observations have not been reported previously.
First, grades II to IV and grades III to IV acute GVHD risks were
not different between the 2 populations. Second, chronic
GVHD risks were higher for Whites who received regimens
that did not include ATG. Third, signiﬁcant differences were
not found in survival between the populations. Our ﬁndings
are different from a previous report that compared GVHD
risks and survival after HLA-matched sibling bone marrow
transplantation [2]. In that report, acute and chronic GVHD
risks were higher for younger Whites compared with the
Japanese. We hypothesize in the setting of UCBT that the use
of units mismatched to recipients at the major histocom-
patibility antigens may have ameliorated any advantages
associated with the sharing of minor histocompatibility an-
tigens in the more homogenous Japanese population. There
are also qualitative and quantitative differences in the
composition of bone marrow and UCB grafts leading to dif-
ferences in post-transplant immune reconstitution, which
may explain the observed differences between the current
analysis and the observations after matched sibling trans-
plantation [18,19]. It is also plausible that transplant period
may have inﬂuenced the observations in the current analysis,
which studied transplantations in a more recent era. A recent
report showed lower GVHD risks and improved transplant
outcomes in recent years compared with the previous era
[20], and it may be that current GVHD prophylaxis regimens
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patients, which further ameliorated the impact of genetic
disparity for major and minor histocompatibility antigens.
Compared with the Japanese, who did not receive ATG,
chronic GVHDwas higher inWhites who did not receive ATG
as part of their transplant conditioning but not for those who
received ATG. We hypothesize the Japanese are inherently
less likely to develop chronic GVHD. Despite the higher
chronic GVHD in a subset of the Whites, we did not observe
differences in survival between the treatment groups. Our
ﬁndings differ from that of Narimatsu et al. [21] from the
Japan Cord Blood Bank Network. In that report, chronic
GVHD after UCBT was associated with improved survival. In
the current analyses, despite the higher risks of chronic
GVHD in 1 group, the severity of chronic GVHD was similar
across the groups and may explain our inability to detect
signiﬁcant differences in survival between the groups.
Generally, chronic GVHD adds to the burden of morbidity
and mortality. Our study is limited by lack of data on health-
related quality of life in patients with and without chronic
GVHD. Another limitation is differential follow-up; non-
ATGecontaining preparative regimens for Whites is rela-
tively recent, allowing for a median follow-up time of 3 years
compared with 4 to 5 years for the other 2 groups. With
extended follow-up it is possible that differences may exist
between the non-ATG group and the other groups.
ATG is routinely included in the conditioning regimen
package for UCBT in the United States and Europe to promote
engraftment and lower GVHD risks [22]. However, ATG is
seldom used for UCBT in Japan. Although we were unable to
study immune recovery, delayed immune recovery and
higher rate of infections with ATG is well documented [23]
and has led to increasing use of ﬂudarabine [24-26]. In the
current analysis, we observed an absolute survival difference
of 4% between the Japanese and Whites who did not receive
ATG compared with an absolute difference of 10% between
the Japanese and Whites who received ATG, suggesting that
avoiding ATG-containing transplant conditioning regimens
might be better for long-term survival.
Ethnic differences are reportedly contributors to related
and unrelated bonemarrow transplantation outcomes [2,27-
29]. Ballen et al. [30] reported inferior survival in African
Americans after UCBT, but the etiology for higher mortality
was attributed to these patients having received units with
greater HLA disparity and lower cell dose compared with
Whites. In our study, despite the Japanese patients having
received UCB units with lower cell dose compared with the
U.S. Whites, survival rates were similar. We hypothesize that
a minimum cell dose is needed for engraftment and selecting
units with cell doses in excess of the minimum required does
not lower mortality risks. It is possible differences may exists
in the minimum cell dose for different populations. In the
United States, reports from the Center for International Blood
and Marrow Transplant have consistently shown the mini-
mum required cell dose as 3.0 107/kg. Among the Japanese,
the minimum cell dose is 2.0  107/kg. Others have shown
better matching between UCB units and their recipients can
lower some of the excess TRM associated with UCBT [9]. We
were unable to test for the effect of matching at the HLA-C
locus or matching at the allele level, because these data
were not available for all patients in the current analyses. At
least among Whites, most transplantations reported in the
current analysis are likely to be mismatched at 3 or greater
HLA loci when considering allele-level HLA-match [31].
Whether there exist differences in survival between theJapanese and Whites when units are better HLA matched
remains to be tested.
In summary, unlike in the setting of HLA-matched sibling
transplantation, we did not observe differences in acute
GVHD or overall mortality after UCBT between the Japanese
and U.S. Whites. The observed higher chronic GVHD in a
subset of transplantations in the United States warrants a
study that focuses on health-related quality of life and long-
term survival to fully evaluate the effect of chronic GVHD in
these patients. Our ﬁndings are limited to children with
acute leukemia. Because most older patients in the United
States receive 2 UCB units and those in Japan a single UCB
unit, a comparative analyses as performed in children re-
mains a challenge.
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